Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
3.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Blood
; 137(1): 39-48, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730585
4.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289656
5.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
6.
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Am J Hematol
; 96(10): 1211-1222, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251048
7.
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Br J Haematol
; 184(6): 1006-1010, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30537212
8.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood
; 130(20): 2196-2203, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28874350
9.
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
Biol Blood Marrow Transplant
; 24(10): 2133-2138, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909154
10.
Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
Br J Haematol
; 200(4): 524-527, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484627
11.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458003
12.
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
Biol Blood Marrow Transplant
; 22(9): 1543-1551, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27131863
13.
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Haematologica
; 106(1): 255-258, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32079691
14.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Lancet Oncol
; 16(3): 284-92, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683846
15.
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Br J Haematol
; 168(5): 663-70, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25316653
16.
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.
Curr Oncol Rep
; 17(9): 42, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26201264
17.
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Biol Blood Marrow Transplant
; 20(12): 2004-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25175794
18.
Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Oncologist
; 19(12): 1249-57, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25342313
19.
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Invest New Drugs
; 32(6): 1246-57, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142258
20.
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Am J Hematol
; 94(4): E90-E93, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592080